Evidence map›Paper›PMID 40836932›Full record

ReviewJournal of orthopaedic translation2025

Innovative strategies for bone organoid: Synergistic application and exploration of advanced technologies.

Xu Lou, Qirong Zhou, Zhenglin Dong, Long Bai, Jiacan Su, Hua Yue

Abstract readReview
In one paragraph

Review in Journal of orthopaedic translation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Bone Organoids: A Novel Tool for Modeling and Managing Skeletal Disorders in Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. From scientific discovery to orthopaedic clinical innovation.Journal of orthopaedic translation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xu LouDepartment of Osteoporosis and Bone Disease, Shanghai Clinical Research Center of Bone Disease, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Qirong ZhouDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Zhenglin DongDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Long BaiOrganoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Jiacan SuOrganoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Hua YueDepartment of Osteoporosis and Bone Disease, Shanghai Clinical Research Center of Bone Disease, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone organoids, as three-dimensional (3D) biomimetic constructs, have emerged as a promising platform for studying bone development, disease modeling, drug screening, and regenerative medicine. This review comprehensively explores innovative strategies driving bone organoid advancements, emphasizing the integration of cutting-edge technologies such as bioprinting, artificial intelligence, assembloids, and gene editing. While 3D bioprinting enhances spatial precision and structural complexity, artificial intelligence accelerates organoid optimization through data-driven approaches. Assembloids enable the assembly of multicellular systems to better replicate bone tissue microenvironments, whereas gene editing refines disease modeling and functional modifications. Despite these advancements, challenges remain, including the lack of vascularization, insufficient mechanical stimulation, and standardization issues across different models. Also, the clinical translation of bone organoids necessitates the establishment of rigorous evaluation frameworks, ethical guidelines, and regulatory policies to ensure their reproducibility and safety. Looking ahead, interdisciplinary convergence will be critical for constructing physiologically relevant " The Translational Potential of this Article: This review provides a comprehensive overview of cutting-edge strategies for constructing bone organoids, emphasizing their integration with advanced technologies such as bioprinting, artificial intelligence, assembloids, and gene editing. By systematically discussing their applications in bone development, disease modeling, drug screening, and regenerative medicine, this article bridges the gap between experimental models and clinical translation. The insights into vascularization, skeletal patterning, and high-throughput screening platforms offer a foundation for developing physiologically relevant bone organoids with enhanced fidelity and functionality. These advancements hold significant potential for accelerating personalized medicine, facilitating preclinical evaluation of therapeutics, and ultimately improving treatment outcomes for skeletal diseases.

Indexed as

Artificial intelligenceAssembloidBioprintingBone organoidGene editingOsteoporosis

Identifiers

PMID40836932
PMCPMC12362404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.